Ginkgo Bioworks Inc.

6.00
0.34 (6.01%)
At close: Apr 02, 2025, 3:59 PM
5.64
-5.87%
After-hours: Apr 02, 2025, 08:00 PM EDT

Company Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming.

Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum.

The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform.

Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Inc.
Ginkgo Bioworks  Inc. logo
Country United States
IPO Date Apr 19, 2021
Industry Biotechnology
Sector Healthcare
Employees 834
CEO Dr. Jason Kelly Ph.D.

Contact Details

Address:
27 Drydock Avenue
Boston, Massachusetts
United States
Website https://www.ginkgobioworks.com

Stock Details

Ticker Symbol DNA
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001830214
CUSIP Number 37611X100
ISIN Number US37611X1000
Employer ID 87-2652913
SIC Code 2836

Key Executives

Name Position
Dr. Jason Kelly Ph.D. Founder, Chief Executive Officer & Director
Bartholomew Canton Ph.D. Founder, Chief Technology Officer & Secretary
Dr. Reshma P. Shetty Founder, President, Chief Operating Officer & Director
Mark E. Dmytruk Chief Financial Officer
Austin Che Ph.D. Founder, Head of Strategy & Treasurer
Joshua Dunn Head of Design
Karen Tepichin General Counsel & Secretary
Samantha Sutton Head of People
Steven P. Coen CPA Chief Accounting Officer
Thomas Knight Jr. Founder

Latest SEC Filings

Date Type Title
Mar 24, 2025 144 Filing
Mar 21, 2025 144 Filing
Mar 20, 2025 144 Filing
Mar 19, 2025 144 Filing
Mar 18, 2025 144 Filing
Mar 17, 2025 4 Filing
Mar 17, 2025 144 Filing
Mar 14, 2025 144 Filing
Mar 13, 2025 144 Filing
Mar 12, 2025 144 Filing